Neuroblastoma: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 200+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Withdrawn

  Comparing 123I-MIBG and 18F-MFBG Imaging in Patients With Newly Diagnosed, High Risk Neuroblastoma

  NCT06858501· Children's Oncology Group· Updated 16 Sept 2026

  “Other - Protocol moved to Withdrawn”Registry text, quoted unchanged. Source

• Suspended

  Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma, GD2-CAR PERSIST Trial

  NCT04539366· National Cancer Institute (NCI)· Updated 5 Aug 2026

  “Other - review of safety data”Registry text, quoted unchanged. Source

• Terminated

  Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma

  NCT04751383· National Cancer Institute (NCI)· Updated 30 Jun 2026

  “Drug supply issues”Registry text, quoted unchanged. Source

• Terminated

  GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2

  NCT05130255· Y-mAbs Therapeutics· Updated 18 Jun 2026

  “Decision by Sponsor”Registry text, quoted unchanged. Source

• Terminated

  67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk, Relapsed, Refractory Neuroblastoma

  NCT04023331· Clarity Pharmaceuticals Ltd· Updated 16 Sept 2025

  “Sponsor decision”Registry text, quoted unchanged. Source

• Terminated

  Evaluation of 2 Intensification Treatment Strategies for Neuroblastoma Patients With a Poor Response to Induction

  NCT03165292· Gustave Roussy, Cancer Campus, Grand Paris· Updated 2 Sept 2025

  “The Sponsor has been notified of an interruption in the international supply, and there is a possibility that 131I-mlBG would be unavailable to patients randomised to arm A of the trial”Registry text, quoted unchanged. Source

• Terminated

  9-ING-41 in Pediatric Patients With Refractory Malignancies.

  NCT04239092· Actuate Therapeutics Inc.· Updated 17 Jul 2025

  “The decision to conclude study was made to optimize the clinical study design and protocol to further evaluate the safety profile of elraglusib (9-ING-41) in pediatric and adult patients with refractory Ewings Sarcoma.”Registry text, quoted unchanged. Source

• Terminated

  Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults

  NCT04530487· M.D. Anderson Cancer Center· Updated 29 Jun 2025

  “PI Request”Registry text, quoted unchanged. Source

• Terminated

  GVAX Plus Checkpoint Blockade in Neuroblastoma

  NCT04239040· Dana-Farber Cancer Institute· Updated 19 Mar 2025

  “Manufacturing issues”Registry text, quoted unchanged. Source

• Terminated

  A Study of Panobinostat in Pediatric Patients With Solid Tumors Including MRT/ATRT

  NCT04897880· Australian & New Zealand Children's Haematology/Oncology Group· Updated 24 Feb 2025

  “Drug supply”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse

  NCT07437963· National Cancer Institute (NCI)· Source

• Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms

  NCT01005654· National Cancer Institute (NCI)· Source

• Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors

  NCT06176989· National Cancer Institute (NCI)· Source

• A Study of Avutometinib for People With Solid Tumor Cancers

  NCT06104488· Memorial Sloan Kettering Cancer Center· Source

• GD2IL18CART Combined With Bevacizumab for Relapsed and Refractory GD2-positive Solid Tumors

  NCT07897968· Universität Münster· Source

• A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors

  NCT06041516· National Cancer Institute (NCI)· Source

• Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

  NCT06395103· Merck Sharp & Dohme LLC· Source

• Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

  NCT06172296· National Cancer Institute (NCI)· Source

• Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma

  NCT06995872· National Cancer Institute (NCI)· Source

• Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

  NCT04284774· National Cancer Institute (NCI)· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 15
• Organoids 2
• Mendelian Randomization Analysis 5
• CRISPR-Cas Systems 5
• Gene Expression Profiling 44
• Sequence Analysis, RNA 5
• Whole Genome Sequencing 4
• Proteomics 20
• Metabolomics 12
• Mass Spectrometry 10
• Flow Cytometry 19
• Immunohistochemistry 20
• Liquid Biopsy 2
• Circulating Tumor DNA 3
• Xenograft Model Antitumor Assays 65
• Positron-Emission Tomography 14
• Magnetic Resonance Imaging 20
• Machine Learning 10
• Deep Learning 4
• Cohort Studies 8
• Genome-Wide Association Study 5

• Biomineralized SERS Nanotags Encode Biomolecular Identity into Machine Learning-Resolvable Fingerprints.

  ACS Appl Mater Interfaces, Sept 2026

• Artificial Intelligence for Diagnosis, Risk Stratification, and Prognosis of Neuroblastoma - A Systematic Review and Meta-Analysis.

  Curr Oncol Rep, Sept 2026

• Multiparametric MRI radiomics for noninvasive risk stratification of pediatric neuroblastoma: a pilot study.

  Sci Rep, Aug 2026

• Application Value of a nomogram integrating contrast-enhanced CT radiomics and clinical indicators in evaluating lymph node metastasis in pediatric peripheral neuroblastoma.

  Cancer Imaging, May 2026

• Cell Analyser in Batch for Neurite (CABaNe), an Automated, High-Throughput ImageJ Macro for Cell and Neurite Analysis.

  eNeuro, Feb 2026

• Predicting neuroblastoma prognosis using machine learning analysis of metabolism-related gene network perturbation.

  BMC Pediatr, Jan 2026

• Multi-Omics Analysis Reveals the Molecular Subtypes and Confirmed the GREM1 as the Core Gene.

  J Gene Med, Jan 2026

• Eugenol as a Novel Neuroblastoma Therapeutic Identified by an Online Prognostic Assessment Platform.

  Front Biosci (Landmark Ed), Dec 2025

• Integrating machine learning and experiments to elucidate the potential molecular mechanisms of methylparaben-induced Alzheimer's disease: evidence from a Tau hyperphosphorylation cell model.

  BMC Neurol, Dec 2025

• An open-source screening platform accelerates discovery of drug combinations.

  Nat Commun, Dec 2025

See which targets of this disease your abstract mentions, and go to the people working on them.